My-trans en es it fr

My-trans Brand names, My-trans Analogs

My-trans Brand Names Mixture

  • No information avaliable

My-trans Chemical_Formula


My-trans RX_link

No information avaliable

My-trans fda sheet

My-trans msds (material safety sheet)

My-trans Synthesis Reference

No information avaliable

My-trans Molecular Weight

309.469 g/mol

My-trans Melting Point

< 25 oC

My-trans H2O Solubility

Soluble as HCl salt

My-trans State


My-trans LogP


My-trans Dosage Forms

Tablets (oral, 1 mg)

My-trans Indication

Used for the symptomatic treatment of parkinsonism.

My-trans Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

My-trans Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

My-trans side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

My-trans Patient Information

My-trans Organisms Affected

Humans and other mammals